Teladoc Health Earnings & Forecasts

Teladoc Health (TDOC) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

분기별 실적 서프라이즈 금액

회계 분기	보고된 날짜	실제 EPS	예상 EPS	놀라다 %
Q2	Jul 29, 2026	$-0.21	$-0.24	12.5 %
Q1	Apr 29, 2026	$-0.36	$-0.37	2.70 %
Q4	Feb 25, 2026	$-0.14	$-0.21	33.3 %
Q3	Oct 29, 2025	$-0.20	$-0.24	16.7 %

Quarterly Revenue (Billions)

분기별 수익 깜짝 금액

회계 분기	보고된 날짜	실제 수익	예상 수익	놀라다 %
Q2	Jul 29, 2026	$606.93M	$615.58M	-1.41 %
Q1	Apr 29, 2026	$613.85M	$610.93M	0.48 %
Q4	Feb 25, 2026	$642.27M	$634.76M	1.18 %
Q3	Oct 29, 2025	$626.44M	$630.93M	-0.71 %

Teladoc Health Guidance

Teladoc Health (TDOC)은 지난 7월 29, 2026에 Q3 2026의 실적 전망을 발표했습니다. 회사는 주당순이익을 $-0.3 - $-0.2 범위로 전망했으며, 이는 시장 컨센서스 EPS 추정치인 $-0.17보다 높은 수치입니다. Teladoc Health는 또한 해당 기간의 매출을 $569M - $609M 범위로 전망했습니다.

이전 가이던스와 비교하여 Teladoc Health는 매출 전망치를 이전 범위인 하향 조정됨에서 $2.36B - $2.45B로 상향 조정했습니다.

Teladoc Health은 34과 10월 26, 2022 사이에 7월 29, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 7 times and lowered it 15 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$-0.24	$-0.37	$-0.21	$-0.24
Actual	$-0.21	$-0.36	$-0.14	$-0.20
Surprise	+12.5%	+2.70%	+33.3%	+16.7%
Revenue
Estimate	$615.6M	$610.9M	$634.8M	$630.9M
Actual	$606.9M	$613.8M	$642.3M	$626.4M
Surprise	-1.41%	+0.48%	+1.18%	-0.71%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$-0.21	$-0.11	$-0.24	$-0.20
Revenue
Consensus	$591.0M	$602.9M	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

Why Teladoc Stock is Getting Crushed Wednesday After Hours

Teladoc stock is sinking Wednesday after the company reported Q2 results and updated guidance. Here are the key figures to know.

Chris Katje

PRO
Teladoc Health Sees Q3 GAAP EPS $(0.30)-$(0.20) vs $(0.18) Est; Sees Sales $569.000M-$609.000M vs $629.252M Est

Teladoc Health (NYSE:TDOC) is looking for Q3 GAAP EPS of $(0.30)-$(0.20) vs $(0.18) analyst estimate. sees sales of $569.000 million-$609.000 million vs $629.252 million analyst estimate.

Benzinga Newsdesk

PRO
Teladoc Health Raises FY2026 GAAP EPS Guidance from $(1.05)-$(0.75) to $(1.00)-$(0.75) vs $(0.92) Est; Lowers FY2026 Sales Guidance from $2.481B-$2.576B to $2.362B-$2.447B vs $2.508B Est

Teladoc Health (NYSE:TDOC) raises FY2026 GAAP EPS guidance from $(1.05)-$(0.75) to $(1.00)-$(0.75) vs $(0.92) analyst estimate. Lowers FY2026 sales outlook from $2.481 billion-$2.576 billion to $2.362 billion-$2.447

Benzinga Newsdesk

PRO
Teladoc Health Q2 EPS $(0.21) Beats $(0.25) Estimate, Sales $606.927M Miss $615.391M Estimate

Teladoc Health (NYSE:TDOC) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.25) by 16 percent. This is a 10.53 percent decrease over losses of $(0.19) per share from the

Benzinga Newsdesk

Teladoc Shares Fall After Q1 Earnings: What Investors Need To know

Teladoc stock is trading lower after reporting first-quarter financial results. Here are the highlights.

Chris Katje

PRO
Teladoc Health Narrows FY2026 GAAP EPS Guidance from $(1.10)-$(0.70) to $(1.05)-$(0.75) vs $(0.89) Est; Narrows FY2026 Sales Guidance from $2.470B-$2.587B to $2.481B-$2.576B vs $2.509B Est.

Teladoc Health (NYSE:TDOC) narrows FY2026 GAAP EPS guidance from $(1.10)-$(0.70) to $(1.05)-$(0.75) vs $(0.89) analyst estimate. Narrows FY2026 sales outlook from $2.470 billion-$2.587 billion to $2.481 billion-$2.576

Benzinga Newsdesk

Teladoc Health Inc